Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Return on Equity (2020 - 2025)

Historic Return on Equity for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q3 2025 value amounting to 2.81%.

  • Rhythm Pharmaceuticals' Return on Equity rose 74300.0% to 2.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.81%, marking a year-over-year increase of 74300.0%. This contributed to the annual value of 2.72% for FY2024, which is 18700.0% down from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' Return on Equity stood at 2.81%, which was up 74300.0% from 52.01% recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Return on Equity peaked at 0.06% during Q2 2021, and registered a low of 52.01% during Q2 2025.
  • In the last 5 years, Rhythm Pharmaceuticals' Return on Equity had a median value of 0.91% in 2023 and averaged 5.46%.
  • Within the past 5 years, the most significant YoY rise in Rhythm Pharmaceuticals' Return on Equity was 74300bps (2025), while the steepest drop was -468700bps (2025).
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Return on Equity stood at 0.26% in 2021, then crashed by -159bps to 0.66% in 2022, then plummeted by -52bps to 1.01% in 2023, then plummeted by -1473bps to 15.82% in 2024, then skyrocketed by 82bps to 2.81% in 2025.
  • Its last three reported values are 2.81% in Q3 2025, 52.01% for Q2 2025, and 8.3% during Q1 2025.